PHARMACOECONOMIC ANALYSIS OF REFERENCE BEVACIZUMAB: OPPORTUNITY FOR IMPROVED EFFICIENCY

A. Portela Sotelo1, L. Martínez Valdivieso1, I. Martín Niño1, J.A. Santiago Crespo2, A. Flor García1, D. Barreda Hernández1.

1Virgen de la Luz Hospital, Pharmacy Department, Cuenca, Spain. 2Virgen de la Luz Hospital, Oncology Department, Cuenca, Spain.

BACKGROUND AND IMPORTANCE

The recent approval of BEVACIZUMAB BIOSIMILAR (BEVA-BS), raises the possibility of a more efficient drug therapy. REFERENCE BEVACIZUMAB (BEVA-REF) was positioned as the cancer drug with the greatest impact in our Health Area in 2019.

AIM AND OBJECTIVES

To evaluate the pharmacoeconomic impact of BEVA-REF in oncological therapy in 2019 and to analyse measures that promote its therapeutic optimisation, such as more efficient dosage regimens (DR) and implantation of BEVA-BS.

MATERIALS AND METHODS

Descriptive retrospective study realised in a level-II hospital.

Therapeutic optimisation measures analysis, were conducted according to:

- Efficient DR: in concordance with Product Monograph.
- Possibility of implantation BEVA-BS: Hypothetical savings were estimated on 2019’s annual consumption, assuming switching to Beva-BS: a)100% of patients; b)only new patients.


RESULTS

COST BEVA-REF 2019

Highlighting according to indication:

<table>
<thead>
<tr>
<th>Indication</th>
<th>Overall patients: 58</th>
<th>Started treatment: 41 (71%)</th>
<th>Treatment continuations: 17 (29%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast cancer</td>
<td>9 patients 210,106 € (30%)</td>
<td>4 patients 74,139 € (18%)</td>
<td>5 patients 135,967 € (45%)</td>
</tr>
<tr>
<td>Metastatic colorectal cancer</td>
<td>25 patients 205,671 € (29%)</td>
<td>21 patients 169,274 € (42%)</td>
<td>4 patients 36,396 € (12%)</td>
</tr>
<tr>
<td>Ovarian cancer</td>
<td>11 patients 165,346 € (23%)</td>
<td>7 patients 65,776 € (16%)</td>
<td>4 patients 99,570 € (33%)</td>
</tr>
<tr>
<td>Total cost: 710,842€</td>
<td>Total cost: 406,897€</td>
<td>Total cost: 303,945€</td>
<td></td>
</tr>
</tbody>
</table>

THERAPEUTIC OPTIMISATION MEASURES ANALYSIS:

- The most efficient DR in mCRC was prescribed 100%. In the remaining diagnoses, DR was achieved, except ovarian/endometrial cancer, with agreement of 45% and 0% respectively.
- Respect to possibility of implantation BEVA-BS: HYPOTHETICAL SAVINGS

<table>
<thead>
<tr>
<th>HIGHLIGHTING ACCORDING TO INDICATION:</th>
<th>SWITCHING TO BEVA-BS IN ALL PATIENTS</th>
<th>SWITCHING TO BEVA-BS ONLY NEW PATIENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast cancer</td>
<td>92,450€</td>
<td>32,600€</td>
</tr>
<tr>
<td>Metastatic colorectal cancer</td>
<td>90,500€</td>
<td>74,500€</td>
</tr>
<tr>
<td>Ovarian cancer</td>
<td>72,750€</td>
<td>28,900€</td>
</tr>
<tr>
<td>Total savings</td>
<td>312,800€</td>
<td>179,000€</td>
</tr>
</tbody>
</table>

CONCLUSION AND RELEVANCE

The 2019 results show efficient DR, consequently the potential for cost containment, given the incorporation of BEVA-BS in our therapeutic arsenal, would be key for universal access to the best therapeutic option.

Correspondence to: Andrea Portela Sotelo; aportelasotelo@gmail.com

ATC code: L01 - Cytostatics